Telix Pharmaceuticals Limited (TLX)

Market Cap	3.79B
Revenue (ttm)	484.69M
Net Income (ttm)	30.89M
Shares Out	329.55M
EPS (ttm)	0.09
PE Ratio	123.82
Forward PE	18.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	110,878
Open	11.05
Previous Close	10.82
Day's Range	11.04 - 11.10
52-Week Range	10.70 - 30.36
Beta	2.38
Analysts	Strong Buy
Price Target	22.33 (+101.53%)
Earnings Date	n/a

About TLX

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 415
• Stock Exchange: NASDAQ
• Ticker Symbol: TLX
• Website: https://telixpharma.com

Financial Performance

In 2024, Telix Pharmaceuticals's revenue was 783.21 million, an increase of 55.85% compared to the previous year's 502.55 million. Earnings were 49.92 million, an increase of 857.95%.

Financial numbers in AUD

Analyst Forecast

According to 3 analysts, the average rating for TLX stock is "Strong Buy." The 12-month stock price target is $22.33, which is an increase of 101.53% from the latest price.

Price Target

$22.33

(101.53% upside)

Analyst Consensus: Strong Buy